These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 33790049)

  • 1. COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions.
    Landewé RBM; Ramiro S; Mostard RLM
    RMD Open; 2021 Mar; 7(1):. PubMed ID: 33790049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation.
    Janssen MTHF; Ramiro S; Landewé RBM; Magro-Checa C; Mostard RLM
    Ann Rheum Dis; 2021 Oct; 80(10):1362-1363. PubMed ID: 33958327
    [No Abstract]   [Full Text] [Related]  

  • 3. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
    Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
    Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.
    Les Bujanda I; Loureiro-Amigo J; Bastons FC; Guerra IE; Sánchez JA; Murgadella-Sancho A; Rey RG; López JL; Álvarez JS
    Trials; 2021 Jan; 22(1):43. PubMed ID: 33430891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia.
    Pinzón MA; Ortiz S; Holguín H; Betancur JF; Cardona Arango D; Laniado H; Arias Arias C; Muñoz B; Quiceno J; Jaramillo D; Ramirez Z
    PLoS One; 2021; 16(5):e0252057. PubMed ID: 34033648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients.
    Ringer M; Azmy V; Kaman K; Tang D; Cheung H; Azar MM; Price C; Malinis M
    Transpl Infect Dis; 2021 Apr; 23(2):e13556. PubMed ID: 33378571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
    Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
    Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune reactivity during COVID-19: Implications for treatment.
    Napoli C; Benincasa G; Criscuolo C; Faenza M; Liberato C; Rusciano M
    Immunol Lett; 2021 Mar; 231():28-34. PubMed ID: 33421440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients.
    Toda M; Fujii K; Yoshifuji A; Kondo Y; Itoh K; Sekine K; Kikuchi T; Ryuzaki M
    Clin Exp Nephrol; 2022 Jan; 26(1):75-85. PubMed ID: 34436742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.
    Klopfenstein T; Gendrin V; Conrozier T; Gerazime A; Puyraveau M; Zayet S
    Ann Rheum Dis; 2023 Jul; 82(7):e153. PubMed ID: 34162593
    [No Abstract]   [Full Text] [Related]  

  • 13. The shortcomings of tocilizumab in COVID-19.
    Tirupathi R; Bharathidasan K; Areti S; Kaur J; Salim S; Al-Tawfiq JA
    Infez Med; 2020 Dec; 28(4):465-468. PubMed ID: 33257619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles.
    Smolen JS
    Ann Rheum Dis; 2023 May; 82(5):e110. PubMed ID: 33658235
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles.
    Ramiro S; Mostard RLM; Landewé RBM
    Ann Rheum Dis; 2023 May; 82(5):e109. PubMed ID: 33589439
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of Tocilizumab in COVID-19: Single-Center Experience.
    Kaya S; Kavak S
    Biomed Res Int; 2021; 2021():1934685. PubMed ID: 34977235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Calvo-Aranda
    Ramiro S; Mostard R; Landewé RB
    Ann Rheum Dis; 2023 Feb; 82(2):e35. PubMed ID: 33318060
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Kaklamanos
    Ramiro S; Mostard RLM; Landewé RBM
    Ann Rheum Dis; 2023 Jun; 82(6):e135. PubMed ID: 33903095
    [No Abstract]   [Full Text] [Related]  

  • 19. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.
    De Santis M; Voza A; Savevski V; Badalamenti S; Cecconi M; Mantovani A; Selmi C
    Ann Rheum Dis; 2023 May; 82(5):e111. PubMed ID: 33593740
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by De Santis
    Ramiro S; Mostard RLM; Landewé RBM
    Ann Rheum Dis; 2023 May; 82(5):e112. PubMed ID: 33593737
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.